DDX41 and myeloid neoplasm: This discrepancy may be attributed to the distinct molecular mechanisms underlying MDS and AML, DDX41 mutations may play a more prominent role in the early stages of myeloid malignancies, such as MDS, rather than in the more genetically complex AML.